Table VI.

Genotype frequencies of ERCC1 and ERCC2 polymorphisms of control group (n=74) and breast cancer patients (n=71).

Variants	Genotypes	Controls, n (%)	Patients, n (%)	OR (95% CI)	P-valuea
ERCC1 rs11615	GG	40 (54.1)	38 (53.5)	1.00
	GA	27 (36.5)	28 (39.4)	1.09 (0.55–2.18)	0.80
	AA	7 (9.4)	5 (7.1)	0.75 (0.22–2.57)	0.65
	GG/GA	67 (90.6)	66 (92.9)	1.02 (0.53–1.96)	0.95
ERCC2 rs13181	AA	45 (60.8)	49 (69.1)	1.00
	AC	27 (36.5)	19 (26.7)	0.65 (0.32–1.32)	0.23
	CC	2 (2.7)	3 (4.2)	1.38 (0.22–8.62)	0.73
	AA/AC	72 (97.3)	68 (95.8)	0.69 (0.35–1.38)	0.30
ERCC2 rs1799793	CC	54 (72.9)	54 (76.0)	1.00
	CT	1 (1.4)	9 (12.7)	9.00 (1.10–73.50)	0.01b
	TT	19 (25.7)	8 (12.3)	0.42 (0.17–1.04)	0.06
	CC/CT	55 (74.3)	63 (88.7)	0.85 (0.40–1.79)	0.67

^aχ² or Fisher’s exact test.

^bDeviated from Hardy-Weinberg equilibrium.